Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis.

OBJECTIVES Ankylosing spondylitis (AS) is a chronic inflammation of the spine and the sacroiliac joints. Current markers of inflammation, such as C-reactive protein (CRP), are reflecting the production of an acute phase reactant rather than tissue specific inflammation, but the use of CRP as a diagnostic and prognostic marker for AS has not provided the sought accuracy and specificity. We hypothesized that local enzymatic activity in the disease-affected tissue, which is associated with extensive tissue turnover may, by cleavage, modify the CRP produced in the liver. These cleavage products may provide additional information on systemic inflammation as compared to that of full-length CRP. We investigated whether these CRP degradation products would provide additional diagnostic value in AS patients compared to full-length CRP. METHODS CRP fragments were identified by mass-spectrometry. Two fragments were selected for ELISA development. One assay exclusively identified a matrix metalloproteinase (MMP) generated fragment, CRP-MMP, whereas the other assay identified a cathepsin generated fragment, CRP-CAT. Full-length CRP, CRP-MMP and CRP-CAT were measured in serum samples from 40 AS patients and 40 sex- and age-matched controls. RESULTS Full-length CRP was not elevated in AS patients compared to controls, whereas CRP-MMP was elevated by 25% (p<0.001) and CRP-CAT by 50% (p<0.0001). The Area Under Curve of the Receiver-Operator Characteristic curve of CRP-CAT was the highest with 77%. CONCLUSIONS MMP and cathepsin degraded CRP provided more discriminative diagnostic potential compared to that of full-length CRP in this current study. These data suggest that different pools of CRP may provide insight into the inflammation processes in AS.

[1]  M. Karsdal,et al.  Protein fingerprints - relying on and understanding the information of serological protein measurements. , 2011, Clinical biochemistry.

[2]  M. Karsdal,et al.  Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities , 2011, Arthritis research & therapy.

[3]  M. Karsdal,et al.  Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis. , 2011, Clinical biochemistry.

[4]  A. Hashiramoto,et al.  Pathogenesis of Joint Destruction in Rheumatoid Arthritis , 2011, Archivum Immunologiae et Therapiae Experimentalis.

[5]  T. Moilanen,et al.  Leptin enhances MMP-1, MMP-3 and MMP-13 production in human osteoarthritic cartilage and correlates with MMP-1 and MMP-3 in synovial fluid from OA patients. , 2011, Clinical and experimental rheumatology.

[6]  R. Schiotis,et al.  Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis , 2011, Clinical Rheumatology.

[7]  M. Karsdal,et al.  Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: a potential new class of biochemical markers. , 2010, Assay and drug development technologies.

[8]  K. Vlam Soluble and tissue biomarkers in ankylosing spondylitis. , 2010 .

[9]  M. Karsdal,et al.  Matrix metalloproteinase‐9‐mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[10]  M. Karsdal,et al.  Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes. , 2010, Clinical biochemistry.

[11]  M. Karsdal,et al.  Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers--are they the cause or the consequence of the disease? , 2010, Clinical biochemistry.

[12]  M. Karsdal,et al.  A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. , 2010, Clinical biochemistry.

[13]  J. Piette,et al.  Serum cartilage oligomeric matrix protein (COMP) level is a marker of disease activity in relapsing polychondritis. , 2010, Clinical and experimental rheumatology.

[14]  M. Karsdal,et al.  Human macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processes , 2010, BMC cardiovascular disorders.

[15]  A. Mobasheri,et al.  Targeting matrix metalloproteinases in inflammatory conditions. , 2009, Current drug targets.

[16]  J. Zwerina,et al.  Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. , 2009, Arthritis and rheumatism.

[17]  T. Sawai,et al.  Examination of in vivo gelatinolytic activity in rheumatoid arthritis synovial tissue using newly developed in situ zymography and image analyzer. , 2009, Clinical and experimental rheumatology.

[18]  M. Karsdal,et al.  Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[19]  A. Hamzaoui,et al.  Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease. , 2009, Clinical and experimental rheumatology.

[20]  J. Shaughnessy,et al.  The role of Dickkopf-1 in bone development, homeostasis, and disease. , 2009, Blood.

[21]  Martin R Larsen,et al.  The use of titanium dioxide micro-columns to selectively isolate phosphopeptides from proteolytic digests. , 2009, Methods in molecular biology.

[22]  D. Wendling,et al.  Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy. , 2008, Joint, bone, spine : revue du rhumatisme.

[23]  M. Karsdal,et al.  Characterization of metalloprotease cleavage products of human articular cartilage. , 2008, Arthritis and rheumatism.

[24]  Claus Christiansen,et al.  Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity , 2008, Arthritis research & therapy.

[25]  E. Vignon,et al.  Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis. , 2008, Clinical and experimental rheumatology.

[26]  M. Karsdal,et al.  Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood , 2006, Journal of Bone and Mineral Metabolism.

[27]  M. Karsdal,et al.  Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. , 2006, Osteoarthritis and cartilage.

[28]  D J Hunter,et al.  Classification of osteoarthritis biomarkers: a proposed approach. , 2006, Osteoarthritis and cartilage.

[29]  C. Chou,et al.  Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. , 2006, Rheumatology.

[30]  J. Houwing-Duistermaat,et al.  Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study , 2005, Annals of the rheumatic diseases.

[31]  T. Cawston,et al.  Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. , 2005, Current drug targets. Inflammation and allergy.

[32]  R. Bräuer,et al.  Local expression of matrix metalloproteinases, cathepsins, and their inhibitors during the development of murine antigen-induced arthritis , 2004, Arthritis research & therapy.

[33]  M. Pepys,et al.  C-reactive protein and cardiovascular disease: new insights from an old molecule. , 2003, QJM : monthly journal of the Association of Physicians.

[34]  M. Karsdal,et al.  The Type I Collagen Fragments ICTP and CTX Reveal Distinct Enzymatic Pathways of Bone Collagen Degradation , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  J. Volanakis,et al.  Human C-reactive protein: expression, structure, and function. , 2001, Molecular immunology.

[36]  C Combet,et al.  NPS@: network protein sequence analysis. , 2000, Trends in biochemical sciences.

[37]  T. D. Du Clos Function of C-reactive protein , 2000, Annals of medicine.

[38]  G. Stucki,et al.  Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. , 1999, The Journal of rheumatology.

[39]  M. Dougados,et al.  Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. , 1999, The Journal of rheumatology.

[40]  M. Bissell,et al.  An odyssey from breast to bone: Multi‐step control of mammary metastases and osteolysis by matrix metalloproteinases , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[41]  J. Mathews,et al.  Lack of correlation between clinical disease activity and erythrocyte sedimentation rate, acute phase proteins or protease inhibitors in ankylosing spondylitis. , 1986, British journal of rheumatology.

[42]  D. Margulies,et al.  A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells , 1977, Somatic cell genetics.

[43]  E. Kass The pathogenesis of ankylosing spondylitis. , 1975, Annals of clinical research.